Literature DB >> 22139739

A hierarchical rank test for crossover trials with censored data.

Erica Brittain1, Dean Follmann.   

Abstract

We propose an approach to analyze survival time in a crossover clinical trial by performing a primary ranking on whether events occur and a secondary ranking on event times. This hierarchical ranking method is meant to reflect the idea that the goal of therapy is to prevent a clinical event and, failing that, to delay the occurrence of the event, hopefully for a substantial amount of time. We compare our approach with other methods including one method proposed by Feingold and Gillespie, a recommended procedure. The power is similar in many settings, but the hierarchical ranking can have substantially greater power under certain censoring patterns and also under a cure model, or models where treatment induces a substantial delay in some fraction of patients. We additionally feel that the hierarchical ranking method should be more clinically relevant in many settings. The method can also be applied to continuous outcomes censored by a limit of detection, such as HIV viremia.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22139739      PMCID: PMC4770564          DOI: 10.1002/sim.4398

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP).

Authors:  E Brittain; J Palensky; J Blood; J Wittes
Journal:  Stat Med       Date:  1997-03-30       Impact factor: 2.373

2.  The use of subjective rankings in clinical trials with an application to cardiovascular disease.

Authors:  D Follmann; J Wittes; J A Cutler
Journal:  Stat Med       Date:  1992-02-28       Impact factor: 2.373

3.  Cross-over trials in Statistics in Medicine: the first '25' years.

Authors:  Stephen Senn
Journal:  Stat Med       Date:  2006-10-30       Impact factor: 2.373

4.  The analysis of failure time data in crossover studies.

Authors:  L A France; J A Lewis; R Kay
Journal:  Stat Med       Date:  1991-07       Impact factor: 2.373

5.  Regression analysis based on pairwise ordering of patients' clinical histories.

Authors:  Dean A Follmann
Journal:  Stat Med       Date:  2002-11-30       Impact factor: 2.373

6.  Rule-based ranking schemes for antiretroviral trials.

Authors:  L E Bjorling; J S Hodges
Journal:  Stat Med       Date:  1997-05-30       Impact factor: 2.373

7.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

8.  A generalized two-sample Wilcoxon test for doubly censored data.

Authors:  E A Gehan
Journal:  Biometrika       Date:  1965-12       Impact factor: 2.445

Review 9.  Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

Authors:  J D Neaton; D N Wentworth; F Rhame; C Hogan; D I Abrams; L Deyton
Journal:  Stat Med       Date:  1994 Oct 15-30       Impact factor: 2.373

10.  Ranking procedures for arbitrarily restricted observation.

Authors:  N Mantel
Journal:  Biometrics       Date:  1967-03       Impact factor: 2.571

View more
  1 in total

1.  A New Method for Imputing Censored Values in Crossover Designs with Time-to-Event Outcomes Using Median Residual Life.

Authors:  Maryam Jalali; Zahra Bagheri; Najaf Zare; Seyyed Mohammad Taghi Ayatollahi
Journal:  Biomed Res Int       Date:  2020-12-10       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.